美国医疗保险血液透析人群中血红蛋白变异性特征描述方法的比较 - Suppr

Suppr

超能文献

Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population.

作者信息

Arneson Thomas J, Zaun David, Peng Yi, Solid Craig A, Dunning Stephan, Gilbertson David T

出版信息

Nephrol Dial Transplant. 2009 May;24(5):1378-83. doi: 10.1093/ndt/gfp018. Epub 2009 Feb 5.

DOI:10.1093/ndt/gfp018

PMID:19196826

Abstract

摘要

相似文献

Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population.美国医疗保险血液透析人群中血红蛋白变异性特征描述方法的比较

Nephrol Dial Transplant. 2009 May;24(5):1378-83. doi: 10.1093/ndt/gfp018. Epub 2009 Feb 5.

Finding a rational approach to ESA therapy--for payers and patients.为支付方和患者寻找合理的促红细胞生成素治疗方法。

Nephrol News Issues. 2007 Sep;21(10):54, 56.

[How to optimize the concept of the variability of haemoglobin in dialysis patients].[如何优化透析患者血红蛋白变异性的概念]

Nephrol Ther. 2008 Dec;4(7):547-8. doi: 10.1016/j.nephro.2008.08.001. Epub 2008 Sep 21.

Case-mix adjusted composite rate--did Medicare get it right?病例组合调整后的综合费率——医疗保险做对了吗？

Nephrol News Issues. 2005 Sep;19(10):44.

Bundling and its potential impact on dialysis service providers.捆绑销售及其对透析服务提供商的潜在影响。

Nephrol News Issues. 2008 Oct;22(11):12, 14, 16-7.

[Change of hemoglobin level: causes and consequences. Renal anemia].

Nephrol Ther. 2008 Oct;4 Spec No 2:9-16. doi: 10.1016/S1769-7255(08)74251-2.

Renal failure and dialysis patients: What the EMS provider should know.肾衰竭与透析患者：急救医疗服务提供者应了解的内容。

Emerg Med Serv. 2005 Jun;34(6):85-92; quiz 112-3.

Haemoglobin, not haematocrit, should be the preferred parameter for the evaluation of anaemia in renal patients.对于评估肾病患者的贫血情况，血红蛋白而非血细胞比容应作为首选参数。

Nephrol Dial Transplant. 2001 May;16(5):1085-7. doi: 10.1093/ndt/16.5.1085.

Anemia of chronic kidney disease: CHOIR and the FDA.慢性肾脏病贫血：CHOIR与美国食品药品监督管理局

Nat Clin Pract Nephrol. 2007 Aug;3(8):406-7. doi: 10.1038/ncpneph0539. Epub 2007 Jun 26.

The financial implications for Medicare of greater use of peritoneal dialysis.更多使用腹膜透析对医疗保险的财务影响。

Clin Ther. 2009 Apr;31(4):880-8. doi: 10.1016/j.clinthera.2009.04.004.

引用本文的文献

High hemoglobin fluctuation was a protective factor for cardiovascular-related death in peritoneal dialysis (PD) patients: A retrospective analysis of 232 patients with PD.高血红蛋白波动是腹膜透析（PD）患者心血管相关死亡的保护因素：对 232 例 PD 患者的回顾性分析。

J Clin Lab Anal. 2022 Jul;36(7):e24548. doi: 10.1002/jcla.24548. Epub 2022 Jun 12.

Effects of the route of erythropoietin administration on hemoglobin variability and cardiovascular events in hemodialysis patients.促红细胞生成素给药途径对血液透析患者血红蛋白变异性和心血管事件的影响。

Kidney Res Clin Pract. 2021 Dec;40(4):724-733. doi: 10.23876/j.krcp.20.260. Epub 2021 Aug 31.

Haemoglobin variability and all-cause mortality in haemodialysis patients: A systematic review and meta-analysis.血红蛋白变异性与血液透析患者全因死亡率：系统评价和荟萃分析。

Nephrology (Carlton). 2019 Dec;24(12):1265-1272. doi: 10.1111/nep.13560. Epub 2019 Feb 28.

The role of hemoglobin variability as a prognostic indicator in peritoneal dialysis patients: a retrospective descriptive study.血红蛋白变异性作为腹膜透析患者预后指标的作用：一项回顾性描述性研究。

Int Urol Nephrol. 2018 Jan;50(1):167-171. doi: 10.1007/s11255-017-1722-8. Epub 2017 Nov 1.

Does erythropoietin cause hemoglobin variability--is it 'normal'?促红细胞生成素会导致血红蛋白变异性吗——这是“正常的”吗？

PLoS One. 2014 Apr 7;9(4):e92890. doi: 10.1371/journal.pone.0092890. eCollection 2014.

Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: is it feasible?开发促红细胞生成素处方模拟工具以提高促红细胞生成素刺激剂处方能力：是否可行？

BMC Nephrol. 2011 Feb 18;12:11. doi: 10.1186/1471-2369-12-11.

Hemoglobin variability does not predict mortality in European hemodialysis patients.血红蛋白变异性与欧洲血液透析患者的死亡率无关。

J Am Soc Nephrol. 2010 Oct;21(10):1765-75. doi: 10.1681/ASN.2009101017. Epub 2010 Aug 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验